Marc Buyse
ScD
Chief Scientific Officer
👥Biography 个人简介
Marc Buyse has made major contributions to the statistical validation of surrogate endpoints in oncology clinical trials — particularly validating whether progression-free survival (PFS) can serve as a reliable surrogate for overall survival (OS). His meta-analytic approaches for surrogate endpoint validation have informed regulatory decisions about acceptable endpoints for cancer drug approval and continue to be applied across multiple tumor types.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Marc Buyse 的研究动态
Follow Marc Buyse's research updates
留下邮箱，当我们发布与 Marc Buyse（International Drug Development Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment